Article
Oncology
Lin Shi, Jinying Lu, Da Zhong, Meijuan Song, Jian Liu, Wenhua You, Wen-Hui Li, Lin Lin, Dongyan Shi, Yun Chen
Summary: Mucosal-associated invariant T (MAIT) cells in non-small cell lung cancer (NSCLC) patients exhibit an exhausted tumor-promoting phenotype and the subset of circulating MAIT cells can predict the response to anti-PD-1 immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Javier Peinado-Serrano, Amancio Carnero
Summary: Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide. Treatment options include surgery, chemotherapy, molecular targeted therapy, and radiation. The heterogeneity of molecular profiles contributes to variations in patients' overall survival and therapeutic responses. Identifying prognostic and predictive gene signatures can improve therapeutic decision-making and clinical outcomes for NSCLC patients.
Article
Oncology
Masayuki Sato, Yukihiro Umeda, Tetsuya Tsujikawa, Tetsuya Mori, Miwa Morikawa, Masaki Anzai, Yuko Waseda, Maiko Kadowaki, Yasushi Kiyono, Hidehiko Okazawa, Tamotsu Ishizuka
Summary: Changes in F-18-FLT PET parameters may serve as an early predictive biomarker for the response to anti-PD-1 therapy in NSCLC patients, but pseudoprogression should be noted in imaging at 2 weeks after treatment initiation.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Mariasole Perrone, Edoardo Raimondi, Matilde Costa, Gianluca Rasetto, Roberto Rizzati, Giovanni Lanza, Roberta Gafa, Giorgio Cavallesco, Nicola Tamburini, Pio Maniscalco, Maria Cristina Mantovani, Umberto Tebano, Manuela Coeli, Sonia Missiroli, Massimo Tilli, Paolo Pinton, Carlotta Giorgi, Francesco Fiorica
Summary: Despite advances in treatments and research, the prognosis for non-small cell lung cancer (NSCLC) remains poor. This study investigated the correlation between inflammatory radiomic features and clinical outcomes in NSCLC patients. By analyzing computed tomography (CT) images, the researchers identified specific radiomic signatures that accurately predicted patients' inflammatory levels and clinical outcomes. They developed and validated a radiomic model to predict the evolution pattern of NSCLC tumors in a non-invasive way, allowing for personalized and accelerated patient management.
Article
Oncology
Julie Lecuelle, Laure Favier, Clea Fraisse, Aurelie Lagrange, Coureche Kaderbhai, Romain Boidot, Sandy Chevrier, Philippe Joubert, Bertrand Routy, Caroline Truntzer, Francois Ghiringhelli
Summary: In patients with non-small cell lung cancer (NSCLC), high expression of endogenous retroviruses (ERVs) was associated with better treatment efficacy and immune response. This study found that high MER4 ERV expression was associated with improved progression-free survival (PFS) and overall survival (OS) in NSCLC patients receiving immune checkpoint inhibitors (ICI). Additionally, adding MER4 to existing transcriptomic signatures improved the predictive power for response to ICI.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Pathology
Yanli Zhu, Sheng Li, Haiyue Wang, Wenhao Ren, Kaiwen Chi, Jianghua Wu, Luning Mao, Xiaozheng Huang, Minglei Zhuo, Dongmei Lin
Summary: This study validates a new molecular subtype classification for small-cell lung carcinoma (SCLC) and explores its clinical significance through immunohistochemical analysis. The results identify four main subtypes and a quadruple-negative subtype, and examine their associations with clinicopathological features. Additionally, no significant difference in survival was observed among the molecular subtypes.
JOURNAL OF CLINICAL PATHOLOGY
(2023)
Review
Oncology
Beatriz Honrubia-Peris, Javier Garde-Noguera, Jose Garcia-Sanchez, Nuria Piera-Molons, Antonio Llombart-Cussac, Maria Leonor Fernandez-Murga
Summary: Immune checkpoint inhibitors have revolutionized the treatment of advanced NSCLC, but current biomarkers such as PD-L1 and PD-L1 have limitations. New non-invasive biomarkers are urgently needed to improve patient selection. Recent advances have focused on developing novel soluble biomarkers for better prediction of treatment response and toxicity in NSCLC patients undergoing immunotherapy.
Article
Medicine, Research & Experimental
Alice Mogenet, Pascal Finetti, Emilie Denicolai, Laurent Greillier, Pascaline Boudou-Rouquette, Francois Goldwasser, Gwenael Lumet, Michele Ceccarelli, Daniel Birnbaum, Davide Bedognetti, Emilie Mamessier, Fabrice Barlesi, Francois Bertucci, Pascale Tomasini
Summary: The ICR signature, a 20-gene expression signature, is independently associated with benefit from anti-PD1/PDL1 ICI in advanced NSCLC patients and has predictive value for treatment outcomes. Further validation in larger retrospective and prospective studies is needed.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Javier Peinado-Serrano, Alvaro Quintanal-Villalonga, Sandra Munoz-Galvan, Eva M. Verdugo-Sivianes, Juan C. Mateos, Maria J. Ortiz-Gordillo, Amancio Carnero
Summary: The search for gene signatures that can predict the response to radiotherapy treatment is important for clinical decision making. This study analyzed gene expression levels in different NSCLC cell lines and identified a six-gene signature that can predict overall survival and progression-free survival in NSCLC patients.
Article
Biochemical Research Methods
Bin Luo, Zujun Que, Xinyi Lu, Dan Qi, Zhi Qiao, Yun Yang, Fangfang Qian, Yi Jiang, Yan Li, Ronghu Ke, Xiaoyun Shen, Hua Xiao, Hegen Li, Erxi Wu, Jianhui Tian
Summary: The study identified potential biomarkers for early NSCLC diagnosis and metastasis prediction through the proteome analysis of plasma exosomes. CFHR5 emerged as a promising prognostic indicator for NSCLC patients. The clinical utility of exosomal biomarkers offers the potential to enhance the management of NSCLC.
BIOLOGICAL PROCEDURES ONLINE
(2023)
Review
Biochemistry & Molecular Biology
Lucile Pabst, Sebastien Lopes, Basil Bertrand, Quentin Creusot, Maria Kotovskaya, Erwan Pencreach, Michele Beau-Faller, Celine Mascaux
Summary: The therapeutic algorithm for lung cancer has been revolutionized by immune checkpoint inhibitors, but the response rate and adverse events remain a challenge. Predictive and prognostic biomarkers are needed to select patients who will respond to treatment. Currently, PD-L1 expression is the only validated biomarker, but its predictive value is imperfect. New molecular features, such as tumor mutational burden, have shown promise in predicting response to immunotherapy. This review summarizes the latest knowledge on predictive and prognostic biomarkers to advance precision immuno-oncology.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Qiongjie Yu, Xuedan Du, Zhen Fang, Xiaolu Mao, Jinting Wu, Bin Wang, Wenfeng Li
Summary: In this study, risk factors for early recurrence in pIIIA-N2 NSCLC patients who underwent radial resection were identified, with smoking history, tumor size, metastatic lymph node ratio, and platelet-to-lymphocyte ratio found to be independent risk factors. Patients with early recurrence had a significantly worse prognosis than those without early recurrence, with a median survival time of 20.6 months compared to 83.1 months. Early recurrence patients were more likely to develop bone metastases.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Marius Ilie, Melanie Beaulande, Elodie Long-Mira, Christophe Bontoux, Katia Zahaf, Salome Lalvee, Marame Hamila, Jonathan Benzaquen, Charlotte Cohen, Jean-Philippe Berthet, Charles-Hugo Marquette, Sandra Lassalle, Veronique Hofman, Paul Hofman
Summary: This study optimized two automated four-plex immunohistochemistry (mIHC) assays and evaluated the repeatability and concordance of cell density assessment. After optimization, the mIHC assay showed sensitive and repeatable assessment of eight diagnostic and predictive biomarkers for non-small cell lung cancer (NSCLC), providing a reliable method for clinical decision-making.
Article
Cell Biology
Yu-kun Zheng, Zhong-shi Zhou, Guang-zhong Wang, Ji-yuan Tu, Huan-bo Cheng, Shang-zhi Ma, Chang Ke, Yan Wang, Qi-pan Jian, Yu-hang Shu, Xiao-wei Wu
Summary: This study found that inhibiting miR-122-5p can activate p53 and hinder the progression of the MVA pathway in non-small cell lung cancer (NSCLC). This leads to a decrease in cell proliferation and migration, and an increase in apoptosis. miR-122-5p interacts with p53 and is negatively correlated with its expression. Thus, miR-122-5p regulates NSCLC by targeting p53, offering potential molecular targets for targeted drug development.
CELL DEATH & DISEASE
(2023)
Article
Biochemistry & Molecular Biology
Angela Marrugal, Irene Ferrer, David Gomez-Sanchez, Alvaro Quintanal-Villalonga, Maria Dolores Pastor, Laura Ojeda, Luis Paz-Ares, Sonia Molina-Pinelo
Summary: HSP90 plays a crucial role in lung adenocarcinoma, with inhibitors showing promise as therapeutic strategies. iTRAQ-based proteomic techniques identified proteins correlated with response to HSP90 inhibitors, revealing potential targets for improving clinical efficacy in patients with lung adenocarcinoma.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
